NMS·Healthcare·$423M·#404 / 520 in Healthcare
NMRA Neumora Therapeutics, Inc.
27HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY39
VALUATION50
GOVERNANCE71
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
N/A
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
11 months
33
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
53.0%
52
< 25% strong
Price / Sales
Market cap relative to trailing revenue
N/A
50
< 3x strong
Rule of 40
Growth rate plus operating margin
N/A
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
23.9%
91
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+12.9%
31
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE NMRA WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when NMRA's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.